

# Strategies in the Prevention and Management of Ventilator-Associated Pneumonia

FREDRIC M. PIERACCI, M.D., M.P.H., PHILIP S. BARIE, M.D., M.B.A.

*From the Departments of Surgery and Public Health, Weill Medical College, Cornell University, New York, New York*

---

Ventilator-associated pneumonia (VAP) is a leading cause of morbidity and mortality in the intensive care unit. Prevention of VAP is possible through the use of several evidence-based strategies intended to minimize intubation, the duration of mechanical ventilation, and the risk of aspiration of oropharyngeal pathogens. Current data favor the quantitative analysis of lower respiratory tract cultures for the diagnosis of VAP, accompanied by the initiation of broad-spectrum empiric antimicrobial therapy based on patient risk factors for infection with multi-drug-resistant pathogens and data from unit-specific antibiograms. Eventual choice of antibiotic and duration of therapy are selected based on culture results and patient stability, with an emphasis on minimization of unnecessary antibiotic use.

---

**V**ENTILATOR-ASSOCIATED PNEUMONIA (VAP), defined as pneumonia occurring 48 to 72 hours after endotracheal intubation, remains the most common intensive care unit (ICU) infection among mechanically ventilated patients and a major source of health care resource consumption. Unfortunately, the emergence of VAP as an ICU epidemic is partially iatrogenic. Nonspecific diagnostic criteria, indiscriminate antibiotic use, and unclear therapeutic endpoints have all contributed to increased episodes of VAP caused by multidrug-resistant (MDR) pathogens. In turn, MDR pathogens increase the likelihood of inadequate initial antimicrobial therapy, which exerts further selection pressure for these pathogens, and results in higher mortality. Many aspects of the prevention, diagnosis, and treatment of VAP remain controversial. However, several evidence-based strategies, reviewed herein, can effectively curtail the burden of VAP.

---

Dr. Pieracci is a Fellow in Surgery and Public Health at the Weill Medical College of Cornell University. He is supported by a Surgical Infection Society Foundation Fellowship in Outcomes Research.

Dr. Barie is the President-Elect of the Society of Critical Care Medicine and Past-President of the Surgical Infection Society and the Eastern Association for the Surgery of Trauma. He has a longstanding interest in issues surrounding nosocomial lung infection in the intensive care unit.

Address correspondence and reprint requests to Philip S. Barie, M.D., M.B.A., Department of Surgery, P713A New York-Presbyterian Hospital, 525 East 68th Street, New York, NY 10021.

## Classification

Pneumonia is defined as inflammation of the lung parenchyma caused by infection, and has traditionally been dichotomized into nosocomial- (acquired in an inpatient setting) and community-acquired (acquired in an outpatient setting).<sup>1</sup> However, it is now recognized that pneumonia in outpatients with recent health care contacts, termed healthcare-associated pneumonia (HCAP), is distinct clinically and microbiologically from community-acquired pneumonia (CAP). Compared with CAP, patients with HCAP have significantly higher rates of infection with MDR pathogens, increased mortality, and incur a prolonged hospitalization and greater hospital charges.<sup>2</sup> Instead, HCAP behaves similar to hospital-acquired pneumonia (HAP). Patients with VAP, a subset of HAP and the focus of this review, incur especially poor outcomes.<sup>2</sup> The current classification scheme for pneumonia, as outlined in the recent American Thoracic Society Guidelines for the Management of Adults with HAP, VAP, and HCAP,<sup>3</sup> is summarized in Table 1.

Further distinction is made between early-onset VAP (occurring <5 days after intubation) and late-onset VAP (occurring  $\geq$ 5 days after intubation). Early-onset VAP is often consequential to aspiration of gastric contents, and is caused by predominantly antibiotic-sensitive bacteria such as methicillin-sensitive *Staphylococcus aureus* (MSSA), *Streptococcus pneumoniae*, and *Haemophilus influenzae*.<sup>2-5</sup> Conversely, patients with late-onset VAP are at increased risk for infection with MDR pathogens (e.g.,

TABLE 1. Classification Scheme for Pneumonia

Classification	Definition
HCAP	Pneumonia that occurs in patients who were hospitalized in an acute care hospital for 2 or more days within 90 days of the infection; resided in a nursing home or long-term care facility; received recent intravenous antibiotic therapy, chemotherapy, or wound care within the past 30 days of the current infection; or attended a hospital or hemodialysis clinic.
HAP	Pneumonia that occurs >48 hours from the time of admission.
VAP	Pneumonia that occurs more than 48–72 hours after endotracheal intubation and mechanical intubation.
CAP	All other.

Adapted from American Thoracic Society Guidelines for the Management of Adults with Hospital-Acquired, Ventilator-Associated, and Healthcare-Associated Pneumonia.<sup>3</sup>

methicillin-resistant *S. aureus* [MRSA], *Pseudomonas aeruginosa*, or *Acinetobacter* species).

### Epidemiology

VAP comprises nearly one-third of all ICU infections.<sup>4–7</sup> The incidence of VAP depends upon the diagnostic criteria used, and thus varies markedly in published reports. Clinical criteria alone overestimate the incidence of VAP compared with microbiologic or histologic data.<sup>8,9</sup> Safdar et al.<sup>10</sup> performed a systematic review of 89 studies in which the incidence of VAP among mechanically ventilated patients was reported. Despite substantial heterogeneity of diagnostic criteria, the authors reported a pooled incidence of VAP of 22.8 per cent (95% confidence interval [CI] 18.8–26.9%). The National Nosocomial Infection Surveillance system reported recently that VAP occurred at a rate of 7.5 cases per 1000 ventilator days in medical ICUs and 13.6 per 1000 ventilator days in surgical ICUs.<sup>11</sup> The incidence of VAP varies with the duration of mechanical ventilation, increasing at a rate of 3 per cent per day during the first 5 days, 2 per cent per day during days 5–10, and 1 per cent per day after that.<sup>12</sup>

Risk factors for VAP are summarized in Table 2. Perhaps most important is airway intubation itself. The risk of HAP increases 6- to 20-fold in mechanically ventilated patients;<sup>6,13,14</sup> patients with respiratory failure managed with noninvasive, positive-pressure ventilation have a lower incidence of pneumonia.<sup>15–17</sup> VAP is especially common in patients with ARDS, owing to prolonged mechanical ventilation and devastated local airway host defenses.<sup>18–20</sup>

Whether VAP is an independent risk factor for mortality is controversial.<sup>21</sup> Most recent series have re-

TABLE 2. Risk Factors for VAP

Age ≥60 years
Acute respiratory distress syndrome (ARDS)
Chronic obstructive pulmonary disease or other underlying pulmonary disease
Coma or impaired consciousness
Serum albumin <2.2 g/dL
Burns, trauma
Blood transfusion
Organ failure
Supine position
Large-volume gastric aspiration
Sinusitis
Immunosuppression

ported a crude mortality rate in patients with VAP of 9 per cent to 27 per cent,<sup>5,22–25</sup> although rates can exceed 75 per cent in high-risk patients infected with MDR organisms.<sup>18,26</sup> Assignment of attributable mortality in patients with VAP has been problematic because compared with non-VAP patients, patients who develop VAP are systemically more ill upon intubation. Several authors have addressed this issue through a matched cohort study design. Heyland et al.<sup>27</sup> matched 177 patients who developed VAP to controls by age, admission diagnosis, location before ICU, and admission Acute Physiology and Chronic Health Evaluation II score. Patients who developed VAP had a significantly longer ICU length of stay (LOS), but no increase in mortality (23.7% vs 17.7%,  $P = 0.19$ ). Furthermore, attributable mortality was highest for patients infected with high-risk organisms, defined as MRSA, *Pseudomonas*, *Acinetobacter*, and *Stenotrophomonas*. However, appropriate initial empiric therapy may mitigate adverse outcomes.<sup>28</sup>

Hugonnet et al.<sup>29</sup> matched patients with and without VAP by age, severity of illness, and duration of mechanical ventilation before the development of VAP. Compared with non-VAP patients, patients with VAP suffered an increased ICU LOS, duration of mechanical ventilation, ICU costs, but again, not mortality (32.0% vs 24.7%,  $P = 0.26$ ). However, when these and other matched cohort studies were pooled by meta-analysis, patients with VAP were more than twice as likely to die compared with those without VAP (odds ratio [OR] 2.03, 95% CI 1.16–3.56,  $P = 0.03$ ) and incurred a longer ICU LOS and a mean increased ICU cost of \$10,019.<sup>10</sup>

### Pathogenesis

Impaired host immunity and displacement of normal oropharyngeal flora by pathogens predispose the critically ill, mechanically ventilated patient to VAP. Normal nonspecific host defenses, such as the epiglottis, vocal cords, cough reflex, and ciliated epithelium and mucus of the upper airways are bypassed or ren-

dered ineffective during intubation. Bacteria gain access to the lower respiratory tract via aspiration through the endotracheal tube (where they may establish colonies impervious to the effects of antibiotics in the glycocalyx biofilm that coats the lumen of artificial airway devices), migration around it (particularly if cuff inflation pressure is not maintained), or, in rare instances, hematogenous spread from blood stream infections. Displacement of normal flora by pathogens is also necessary for the development of VAP.<sup>30–32</sup> The facial sinuses and stomach may serve as potential pathogen reservoirs, but measures to minimize passage of pathogens from these sources into the lower airways have provided mixed results (see below).

Currently, the most common pathogens isolated from patients with VAP are MRSA (15%), *Pseudomonas* (14%), *Enterobacter* (3%), *E. coli* (3%), and *Acinetobacter* (2%).<sup>5, 23</sup> Because of indiscriminate use of broad-spectrum antibiotics, MDR pathogens are increasingly implicated in VAP.<sup>33–36</sup> Infection with MRSA is particularly common in patients with diabetes mellitus and after traumatic brain injury.<sup>36–38</sup> *P. aeruginosa*, the most common gram-negative pathogen in VAP, is increasingly common with an MDR phenotype, especially to fluoroquinolones<sup>34, 39</sup> and third-generation cephalosporins.<sup>40</sup>

Anaerobic bacteria are isolated infrequently from patients with VAP, although this finding may represent an inability to culture these organisms effectively from the oxygen-enriched environment of the mechanically ventilated airway.<sup>41</sup> Although isolation of fungi such as *Candida* spp. and *Aspergillus fumigatus* from endotracheal aspirates is common, it nearly always represents colonization of the immunocompetent host.<sup>42–45</sup> However, when fungi are isolated from two or more normally sterile sites (e.g., urine and lower respiratory tract) in an immunocompromised patient, systemic antifungal therapy should be considered.

### Prevention

Prevention of VAP requires a thorough understanding of modifiable risk factors. Strict infection control, including hand hygiene with alcohol-based hand disinfectants, gowning, and gloving, minimizes person-to-person transmission of pathogens and is paramount to deterring all ICU infections.<sup>46, 47</sup> Prevention of VAP begins with minimization of endotracheal intubation and the duration of mechanical ventilation. Noninvasive, positive-pressure ventilation should always be considered in lieu of intubation, as patients with respiratory failure managed with noninvasive, positive-pressure ventilation have a lower incidence of VAP.<sup>15–17, 48</sup> Evidence-based strategies to decrease the duration of mechanical ventilation include daily

interruption of sedation,<sup>49</sup> standardized weaning protocols, and adequate ICU staffing.<sup>50</sup>

If endotracheal intubation is mandated, the orotracheal compared with the nasotracheal route may decrease the risk of developing VAP. Holzapfel et al.<sup>51</sup> found that the incidence of VAP in patients who were randomized to orotracheal intubation was nearly one-half that of patients intubated nasotracheally (6% vs 11%). In light of these data and the association between nasotracheal intubation and the development of nosocomial sinusitis,<sup>52</sup> orotracheal intubation is preferred.

Once intubation has occurred, the majority of preventive measures against VAP decrease the risk of aspiration. Maintenance of endotracheal cuff pressure >20 cm H<sub>2</sub>O<sup>53</sup> and continuous aspiration of subglottic secretions achieved through the use of an endotracheal tube equipped with a dorsal lumen significantly reduce the incidence of VAP.<sup>54–59</sup> Furthermore, strong evidence exists that semirecumbent positioning (30°–45° head-up) is protective compared with supine positioning, especially during enteral feeding.<sup>60–62</sup>

Compared with postpyloric feeding, intragastric feeding results in more episodes of gastroesophageal reflux and aspiration.<sup>63</sup> However, recent randomized, controlled trials (RCTs) comparing rates of VAP have produced variable results.<sup>64, 65</sup> Heyland et al.<sup>66</sup> performed a meta-analysis of 11 RCTs and reported a relative risk of 0.77 (95% CI [0.60–1.00],  $P = 0.05$ ) for VAP with postpyloric compared with gastric feedings. Based on these data, most expert recommendations do not differentiate between gastric and postpyloric feeding.<sup>3, 66, 67</sup> Proton pump inhibitors such as erythromycin may facilitate safe intragastric feeding, should this route be used.<sup>68</sup>

The timing of onset of enteral feedings may influence the risk of developing VAP. Initiation of enteral feeds on Day 1 compared with Day 5 resulted in significantly more episodes of VAP (49.3% vs 30.7%,  $P = 0.02$ ) and a longer ICU LOS in one prospective trial of 150 patients.<sup>69</sup> More recently, Schorr et al.<sup>70</sup> reported that enteral nutrition begun  $\leq 48$  hours after the initiation of mechanical ventilation was independently associated with the development of VAP (OR 2.65, 95% CI 1[0.93–3.63],  $P < 0.0001$ ).

Pharmacologic strategies intended to minimize the risk of aspiration of pathogenic bacteria include selective decontamination of the digestive tract (SDD) with topical or systemic antibiotics or antiseptics, and minimization of stress ulcer prophylaxis. Myriad clinical trials have addressed SDD, most of which have reported a significant decrease in the incidence of VAP.<sup>71–76</sup> However, the evidence in favor of SDD has been limited by questionable study methodology,<sup>77</sup> the use of narrow patient subsets from ICUs in which

MDR pathogens were rare, and an increased number of infections caused by MDR bacteria observed in the SSD groups.<sup>78–80</sup> For these reasons, the use of SDD is currently not recommended for the routine prevention of VAP.

Alternatively, oropharyngeal decontamination can be accomplished with a topical antiseptic such as chlorhexidine. Recent RCTs have provided evidence for<sup>81</sup> and against<sup>82</sup> the efficacy of chlorhexidine in the prevention of VAP, but a recent meta-analysis suggests that topical chlorhexidine may be effective for prevention of VAP.<sup>82A</sup>

Stress ulcer prophylaxis is a known risk factor for the development of VAP;<sup>32, 83</sup> its use should be reserved for patients at high risk for gastrointestinal mucosal hemorrhage (*e.g.*, prolonged mechanical ventilation, intracranial hemorrhage, coagulopathy, and glucocorticoid therapy). Randomized controlled trials comparing histamine type-2 antagonists, sucralfate, and antacids have yielded conflicting results;<sup>84–89</sup> no agent is preferred for prophylaxis based solely on efficacy for prevention of VAP.

Ample data document the relationship between blood transfusion and infection risk in surgical,<sup>90–92</sup> trauma,<sup>93</sup> and critically ill patients.<sup>94</sup> Shorr et al.<sup>70</sup> found red blood cell transfusion to be independently associated with the development of VAP (OR 1.89, 95% CI [1.33–2.68],  $P = 0.0004$ ). Early et al.<sup>95</sup> documented a decreased incidence of VAP in a surgical ICU after implementation of an anemia management protocol. After implementation of the protocol, fewer blood transfusions were administered despite equivalent outcomes, and the incidence of VAP decreased from 8.1 per cent to 0.8 per cent ( $P = 0.002$ ).

Several antibiotic administration strategies, including “de-escalation” and antibiotic rotation or “cycling,” have been suggested to prevent VAP caused by MDR pathogens. De-escalation refers to the process of tailoring empiric broad-spectrum antimicrobial coverage to specific pathogens once microbiologic data from lower respiratory tract samples become avail-

able. Discontinuation of unnecessary antibiotics at this point curtails not only the emergence of MDR organisms, but also the risk of drug toxicity. Antibiotic cycling offers the potential for antibiotic classes to be used on a scheduled basis to preserve overall activity against predominant pathogens.<sup>96, 97</sup> Several prospective trials have documented a decreased incidence of VAP,<sup>98, 99</sup> improved initial adequacy of therapy,<sup>28</sup> and decreased mortality<sup>100</sup> after the implementation of scheduled antibiotic rotation. However, these studies have been limited by the use of historical controls, and thus possibly confounded by other changes in care. Furthermore, recent data have challenged the efficacy of antibiotic cycling.<sup>101</sup> Pending further research, cycling of antibiotics may be considered if multiple classes of antibiotics are cycled frequently in conjunction with other strategies to prevent the emergence of MDR organisms.<sup>102</sup>

Finally, staff education programs concerning modifiable risk factors may be cost-effective in preventing VAP. Zazk et al.<sup>103</sup> demonstrated that an education program administered to respiratory care practitioners and intensive care nurses that highlighted correct practices for the prevention of VAP resulted in a significantly decreased incidence of VAP and increased cost savings. Strategies to prevent VAP are listed in Table 3.

### Diagnosis

The goals in diagnosing VAP are to determine if the patient has pneumonia and to determine the etiologic pathogen. Poor specificity is particularly problematic in the diagnosis of VAP because it not only exposes individual patients to unnecessary risk from overtreatment with antibiotics, but also increases selection pressure and thus the emergence of MDR bacteria within the ICU.<sup>34, 104</sup> Conversely, inadequate initial therapy in patients with VAP (poor sensitivity) has been associated consistently with increased mortality that cannot be reduced by subsequent changes in antibiotics.<sup>105</sup>

TABLE 3. *Strategies to Prevent VAP*

Strategy	Recommended	Insufficient Evidence	Reference(s)
Universal infection control precautions	+		46, 47
Orotracheal intubation	+		51, 52
Maintenance of endotracheal cuff pressure >20 cm H <sub>2</sub> O	+		53
Continuous aspiration of subglottic secretions	+		54–59
Semirecumbent positioning	+		60–62
Postpyloric feeding		+	64–67
Postponement of enteral feeding for at least 48 hours after intubation	+		69, 70
Selective decontamination of the digestive tract		+	71–80
Topical antiseptics		+	81, 82
Transfusion restriction	+		70, 95
Antibiotic cycling		+	28, 98–102

The diagnosis of VAP should be considered in the presence of one or more of the following: fever, leukocytosis or leukopenia, purulent sputum, hypoxemia, or a new or evolving infiltrate viewed on chest radiography (CXR). However, several noninfectious respiratory disease processes may mimic these signs, such as congestive heart failure, atelectasis, pulmonary thromboembolism, pulmonary hemorrhage, and ARDS, making clinical criteria alone nonspecific. Fabregas et al.<sup>106</sup> found the presence of a new infiltrate on CXR, along with two of the three aforementioned clinical criteria, to be 69 per cent sensitive and 75 per cent specific for the diagnosis of VAP when compared with *post mortem* histology. Several subsequent reports have confirmed the low specificity of clinical acumen in the diagnosis of VAP,<sup>107–109</sup> and clinically diagnosed VAP is confirmed microbiologically in fewer than 50 per cent of cases.<sup>9, 110, 111</sup>

Pugin et al.<sup>112</sup> standardized clinical, radiographic, and microbiologic criteria into the Clinical Pulmonary Infection Score (CPIS). Temperature, leukocyte count, CXR infiltrates, the appearance and volume of tracheal secretions,  $P_aO_2:F_iO_2$ , and culture and gram stain of tracheal aspirate (0–2 points each) yield a maximum CPIS score of 12 points; a score of >6 points indicates a high probability of VAP. Despite favorable test performance of the CPIS in its initial description, and its subsequent modification to include radiological progression of pulmonary infiltrate,<sup>113</sup> the specificity of CPIS is no better than clinical acumen alone when compared with lower respiratory tract cultures obtained via bronchoscopic bronchoalveolar lavage (BAL) or protected specimen brush (PSB).<sup>114–116</sup> The National Nosocomial Infection Surveillance system diagnostic criteria for nosocomial pneumonia,<sup>117</sup> which include similar combinations of clinical and radiographic parameters, performs equivalently to the CPIS when compared with quantitative lower respiratory tract cultures.<sup>118</sup> Incorporation of results from gram-stained lower respiratory tract samples into the CPIS improves specificity only marginally.<sup>114</sup> However, the negative predictive value of a gram stain showing no organisms in a clinically stable patient approaches 100 per cent.<sup>119</sup>

Because of the low specificity of clinical signs, radiographic criteria, and microscopic examination of lower respiratory tract samples, culture of lower respiratory tract samples before any manipulation of antibiotics is mandatory for a workup of suspected VAP to minimize false-negative results. Two fundamental issues regarding lower respiratory tract samples are debated: The method of specimen collection (invasive vs noninvasive) and the method of specimen analysis (semiquantitative vs quantitative).

Noninvasive techniques include sampling of the

lower respiratory tract via endotracheal aspirates (EAs), blinded plugged telescoping catheter, blinded PSB, and mini-BAL. Endotracheal aspirates are less specific because of an increased likelihood of contamination by oropharyngeal flora (indicated by the presence of squamous epithelial cells on gram stain) and a decreased likelihood that the presence of organisms indicates infection rather than colonization.

Invasive techniques (BAL or PSB) collect lower respiratory tract samples using fiberoptic bronchoscopy. The main theoretical advantage of bronchoscopy is direct visualization of the airways. However, invasive techniques are more expensive and resource-intensive than their noninvasive counterparts, and may not be available readily. Furthermore, although bronchoscopy is generally well-tolerated, a significant reduction in arterial oxygen saturation has been observed for up to 24 hours after the procedure, possibly related to alveolar flooding caused by residual lavage fluid. However, this transient desaturation is of unclear importance, not having been correlated with poorer outcomes.<sup>120</sup>

Irrespective of collection method, respiratory tract cultures may be analyzed using semiquantitative or quantitative microbiology. The crucial issue is distinction of colonization from infection.<sup>121</sup> Whereas semiquantitative microbiology reports growth in terms of ordinal categories (*e.g.*, light, moderate, or heavy), quantitative microbiology reports growth in number of colony forming units (CFUs) per milliliter of aliquot. In the latter case, a threshold value is selected to distinguish colonization from infection. Commonly used thresholds are  $10^3$  CFU/mL for PSB,  $10^4$  CFU/mL for BAL, and  $10^5$  CFU/mL for EA. It is generally recommended that any threshold be lowered at least one order of magnitude if antibiotics have been changed recently or started before sample acquisition.<sup>122</sup>

Endotracheal aspirates possess inferior specificity when compared with blinded PTC<sup>123</sup> and bronchoscopic BAL or PSB.<sup>124–127</sup> Two systematic reviews, one of bronchoscopic BAL<sup>120</sup> and one of blinded invasive techniques,<sup>128</sup> reported similar test characteristics for the two techniques. However, methodologic variability is rampant. Sixteen of 23 studies (70%) in the former review used histology as a reference standard compared with only 4 of 15 studies (27%) analyzed in the latter review. Furthermore, the remainder of studies analyzed in the review of blinded invasive techniques used bronchoscopic BAL or PSB as the reference category. Both reviews reported substantial interstudy variability in sampling technique as well as threshold values. A recent study reported that compared with a reference standard of bronchoscopic BAL (threshold  $10^4$  CFU/mL), blinded plugged telescoping catheter was 77 per cent sensitive and 94 per

cent specific.<sup>126</sup> Thus, despite these limitations, it is likely that bronchoscopic techniques are more specific than blinded techniques, and that both techniques are superior to EAs.

Evidence-based recommendations for the diagnosis of VAP have been difficult to formulate because many RCTs have compared various permutations of collection and analytical methodology, threshold values, and reference categories. The largest RCT of this type compared an invasive, quantitative approach with a noninvasive, semiquantitative approach.<sup>9</sup> A total of 413 patients suspected of VAP were randomized to evaluation with bronchoscopic BAL or PSB with quantitative cultures, or “clinical” management consisting of semiquantitative analysis of EAs. Antibiotic therapy was discontinued in clinically stable patients with negative culture results, regardless of study arm. Compared with the clinical strategy, patients in the invasive group demonstrated decreased 14-day mortality (16% vs 25%,  $P = 0.02$ ), less antibiotic use (11.9 vs 7.7 antibiotic-free days), decreased sepsis-related organ failure, and decreased 28-day mortality after adjustment for severity of illness. The clinical strategy also resulted in more and broader-spectrum antibiotic therapy compared with the invasive strategy, and increased emergence of fungi. It is unclear whether these improved outcomes resulted from the use of an invasive versus a noninvasive strategy or a quantitative versus a semiquantitative strategy.

Two RCTs have compared outcomes of patients with suspected VAP managed with an invasive versus a noninvasive approach when both samples were cultured quantitatively. Sanchez-Nieto et al.<sup>127</sup> randomized 51 patients with suspected VAP to EA versus bronchoscopic BAL or PSB. Initial antibiotic therapy was modified in a significantly higher percentage of invasive patients compared with noninvasive (42% vs 16%,  $P < 0.05$ ), but there was no difference in severity-adjusted mortality, ICU LOS, or duration of mechanical ventilation. Ruiz et al.<sup>129</sup> randomized 76 patients with suspected VAP to EAs versus bronchoscopic BAL or PSB, and found no difference in incidence of antibiotic modification, duration of mechanical ventilation, ICU length of stay, crude mortality, or adjusted mortality. In both studies, antibiotics were continued in all patients with negative cultures.

Shorr et al.<sup>130</sup> performed a meta-analysis of the aforementioned trials comparing EAs (quantitative or semiquantitative) to bronchoscopic quantitative cultures. Although the pooled OR suggested a survival advantage to the invasive approach (OR = 0.62), the result was not significant ( $P = 0.62$ ). However, patients in the invasive group were more likely to undergo changes in antimicrobial regimen.

Recently, the Canadian Critical Care Trials Group

reported the results of analysis of a secondary endpoint of an antibiotic therapy trial of VAP (carbapenem versus carbapenem/fluoroquinolone), showing in 740 patients that sputum sampling by BAL with quantitative microbiology was not different than routine suctioning and laboratory analysis in terms of mortality and antibiotic use.<sup>130A</sup> However, the study was underpowered (anticipated mortality 40%; observed rate 19%), and patients with *Pseudomonas* and MRSA were excluded, making the study difficult to interpret.

In conclusion, samples obtained via bronchoscopic BAL or PSB and then analyzed quantitatively have the highest specificity in diagnosing VAP. Data reporting outcomes in patients managed with an invasive versus a “clinical” strategy are conflicting, although the largest such trial showed a significant survival advantage for patients managed with the invasive/quantitative approach. Several trials demonstrate that patients so managed are also more likely to undergo antibiotic changes (de-escalation). Trials rebutting the use of the invasive/quantitative strategy are limited because patients with negative cultures continued to receive antibiotics, which negates the putative benefit (the ability to discontinue antimicrobial therapy). This last point is of considerable importance because the value of invasive, quantitative specimens lies not with their impact upon the decision to initiate therapy (these cultures will not become available for 48–72 hours), but rather with their effect upon alteration or discontinuation of antibiotic therapy based on final results.

### Therapy

Neither the decision to initiate antimicrobial therapy nor the choice of specific agents involves interpretation of lower respiratory tract cultures, which will not become available for 48 to 72 hours. Rather, the decision to initiate therapy is based on clinical suspicion and microscopic examination of gram-stained lower respiratory samples (Fig. 1). Furthermore, choice of agent is based on individual patient risk factors for infection with MDR organisms (Table 4) and data from institutional antibiograms. The majority of data indicate that antimicrobial therapy may be withheld safely if a gram-stained lower respiratory tract sample reveals no organisms and the patient has no signs of severe sepsis.<sup>130–133</sup> Clinical signs of infection along with a negative gram stain suggest an extrapulmonary source of infection or sterile inflammation (e.g., intracerebral hemorrhage).

Patients with microorganisms visualized on gram stain, or clinical instability, should receive empiric therapy for VAP until the results of lower respiratory tract cultures become available. The primary concern when treating VAP is the administration of “adequate




FIG. 1. VAP management algorithm. VAP, ventilator-associated pneumonia.

TABLE 4. Risk Factors for VAP with MDR Organisms

Late-onset VAP
Antibiotics within previous 90 days
Hospitalization within previous 90 days
Current hospitalization >5 days
Admission from a long-term care/hemodialysis facility
High frequency of antibiotic resistance in the community
Immunosuppressive disease or therapy

therapy,” being collectively at least one antimicrobial agent to which the pathogen is sensitive, in the correct dose, via the correct route of administration, and in a timely manner. A second crucial aspect of VAP therapy involves serial reevaluation and interpretation of initial microbiology so that therapy may be discontinued if no organism is isolated and the patient has not deteriorated clinically; therapy is de-escalated to treat only the specific etiologic pathogen; and an endpoint of therapy may be identified in prospect and adhered to.

Ample data exist detailing the increased mortality associated with inadequate initial antimicrobial therapy in patients with VAP. Iregui et al.<sup>134</sup> showed that delayed therapy (defined as initial antibiotic treatment administered  $\geq 24$  hours after meeting diagnostic criteria for VAP) was independently associated with hospital mortality (OR 7.68, 95% CI [4.50–13.09],  $P <$

0.001). The mean difference in time to antibiotic administration between groups was 16 hours. Similarly, Kollef et al.<sup>28</sup> reported that inadequate initial antimicrobial therapy was an independent risk factor for ICU mortality in patients with gram-negative infections (OR 4.22, 95% CI [3.57–4.98],  $P < 0.001$ ). Alvarez-Lerma et al.<sup>105</sup> demonstrated that attributable mortality from VAP was significantly lower among patients receiving initial appropriate antibiotic treatment compared with receipt of inappropriate treatment (16.2% vs 24.7%;  $P = 0.03$ ). That appropriate initial therapy is essential is underscored by the fact that Alvarez-Lerma et al. demonstrated that switching to appropriate therapy once culture results became available did not ameliorate the excess mortality associated with inadequate initial therapy.

The choice of initial antimicrobial therapy depends on patient risk factors for MDR pathogens and local microbiologic data that may be obtained from the unit-specific antibiogram (Fig. 2). Having a current and frequently updated antibiogram increases the likelihood that appropriate initial antibiotic treatment will be prescribed.<sup>135–137</sup> In general, therapy for patients at risk for infection with a MDR organism should provide coverage against MRSA, *Pseudomonas*, *Acinetobacter*, and extended-spectrum  $\beta$ -lactamase-producing *Klebsiella*. This will likely require at least two drugs,




FIG. 2. Algorithm for selection of initial antimicrobial therapy in suspected VAP. VAP, ventilator-associated pneumonia; MDR, multi-drug-resistant.

one effective against MRSA (e.g., vancomycin or linezolid) and one effective against MDR gram-negative bacilli, particularly *Pseudomonas* (e.g., piperacillin-tazobactam or meropenem). Patients with early-onset VAP and none of the aforementioned risk factors may be treated with narrow-spectrum therapy as outlined in Fig. 2. Unfortunately, in most ICUs, such patients are relatively few.

Antimicrobial therapy for VAP should be administered initially via the intravenous (IV) route. Enteral therapy may be considered if patients demonstrate an adequate response to IV therapy, gastrointestinal function is normal, and the antibiotics used possess equivalent bioavailability when administered via this route. Conversion to enteral therapy for VAP using linezolid or a fluoroquinolone is effective, assuming the aforementioned criteria are met.<sup>138</sup> A RCT of the adjunctive use of aerosolized tobramycin showed no difference in clinical outcomes between groups, despite significantly increased microbiologic eradication in the tobramycin group;<sup>139</sup> further research into the use of aerosolized antibiotics is needed.

Inadequate dosing of antibiotics leads to the emergence of MDR bacteria and is associated with poorer outcomes in VAP.<sup>140</sup> Appropriate initial dosing of vancomycin (15 mg/kg every 12 h), aminoglycosides (gentamicin or tobramycin 7 mg/kg daily; or amikacin 20 mg/kg daily) and fluoroquinolones (levofloxacin 750 mg daily or ciprofloxacin 400 mg every 8 h) is paramount to achieving adequate therapy (all doses assume normal renal function).

Certain points regarding specific antibiotics warrant further discussion. Most notably, linezolid has emerged as an effective alternative therapy for VAP caused by gram-positive bacteria, and MRSA in particular. Linezolid is theoretically appealing for the treatment of VAP because achievable concentrations in bronchial secretions exceed those in serum, dosing adjustment is not needed for renal failure, and enteral

administration has equivalent bioavailability.<sup>141</sup> Two RCTs demonstrated clinical equivalence of linezolid and vancomycin in the treatment of VAP caused by gram-positive pathogens,<sup>142, 143</sup> and a *post hoc* logistic regression analysis of both studies reported a significantly increased likelihood of clinical cure for linezolid therapy compared with vancomycin.<sup>144</sup> One limitation of these studies involves the possible inadequate initial dosing of vancomycin (1 g every 12 h vs the currently recommended 15 mg/kg every 12 h). However, linezolid is at least as effective as vancomycin in the treatment of gram-positive VAP, and specifically, MRSA infections. Recent cost-effectiveness analyses have also demonstrated significant cost savings associated with the use of linezolid compared with vancomycin.<sup>145, 146</sup>

Abundant data now exist documenting the association between fluoroquinolone use and the emergence of VAP caused by MDR pathogens, particularly *Pseudomonas*.<sup>147–149</sup> Therefore, fluoroquinolone use in the treatment of VAP should be judicious, based on frequently updated institutional antibiograms.

Whereas multidrug therapy is usually necessary to achieve adequate empiric coverage in patients with suspected VAP until culture results become available, combination therapy directed against a specific pathogen (e.g., “double-coverage” of *Pseudomonas*) is unlikely to provide benefit and may worsen outcomes. Neither *in vitro* nor *in vivo* synergy of such combination therapy has been demonstrated consistently.<sup>150, 151</sup> A meta-analysis of all trials of  $\beta$ -lactam monotherapy versus  $\beta$ -lactam-aminoglycoside combination therapy for immunocompetent patients with sepsis, including 64 trials and 7586 patients, found no difference in mortality (relative risk 0.90, 95% CI [0.77–1.06]) or the development of resistance.<sup>152</sup> In fact, clinical failure was more common with combination therapy.

After initiation of adequate antimicrobial therapy

for suspected VAP, results of lower respiratory tract cultures may reveal no growth or insignificant growth (below a predetermined threshold value); significant (above threshold) growth of a pathogen sensitive to a narrow-spectrum agent; or significant growth of a pathogen sensitive only to a broad-spectrum agent. Regarding the first scenario, data indicate that antimicrobial therapy may be discontinued safely as long as the patient has not deteriorated clinically.<sup>130–133</sup> In the second scenario, therapy is de-escalated to a narrow-spectrum agent with activity against the pathogen isolated. In the last scenario, the initial broad-spectrum agent to which the pathogen is susceptible is continued.

The goal of adequate empiric therapy is to initiate a combination of antibiotics likely to cover all possible etiologic pathogens, followed by tailored therapy if possible. The ideal treatment of suspected VAP thus involves an initial period of perfect sensitivity followed by a period of perfect specificity, once microbiology results are available. In this fashion, no patient with VAP is untreated, and no patient without VAP is treated after microbiologic data are available.

Once pathogen-specific therapy has been initiated, its duration must be determined such that prolonged and unnecessary periods of antibiotic administration are avoided. Resolution of clinical and radiographic parameters typically lags the eradication of infection.<sup>153</sup> Vidaur et al.<sup>122</sup> found that improved oxygenation and normalization of temperature occurred within 3 days in VAP patients without ARDS. Dennesen et al.<sup>154</sup> observed a clinical response to therapy of VAP, defined as normalization of temperature, white blood cell count, arterial oxygen saturation, and quality of tracheal aspirates, within 6 days of therapy.

A randomized, multicenter trial of 401 patients with microbiologically proven VAP assigned subjects to receive eight or 14 days of antibiotic therapy.<sup>155</sup> All patients received adequate initial therapy after invasive/quantitative specimen collection, and patients whose therapy ended at 8 days were stable clinically at that time. Patients treated for 8 days had equivalent mortality, ICU LOS, duration of mechanical ventilation, and recurrence of infection despite significantly fewer antibiotic-free days. Recurrent infections were less likely to be caused by MDR pathogens in patients treated for 8 days. However, patients with VAP caused by nonfermenting gram-negative bacilli (e.g., *Pseudomonas*, *Acinetobacter*, and *Stenotrophomonas*) were more likely to develop recurrent pneumonia if treated for 8 days only. Thus, an 8-day course of initially appropriate antimicrobial therapy appears safe and effective provided that the patient has not deteriorated and the pathogen is not a nonfermenting gram-negative bacillus.

In select patients, a shorter course of therapy may be effective for the treatment of VAP. Singh et al.<sup>113</sup> randomized patients with suspected VAP and a CPIS score  $\leq 6$  points to receive standard therapy (physician discretion) versus ciprofloxacin monotherapy, with re-evaluation at Day 3 and discontinuation of antibiotics if the CPIS remained  $\leq 6$ . If the CPIS remained  $\leq 6$  at the 3-day evaluation point, antibiotics were continued in 96 per cent (24/25) of patients in the standard therapy group, but in none of the patients in the experimental therapy group ( $P = 0.0001$ ). Mortality and ICU LOS did not differ despite a shorter duration ( $P = 0.0001$ ) and lower cost ( $P = 0.003$ ) of antimicrobial therapy in the experimental arm.

Patients treated for VAP who do not improve clinically after appropriate antimicrobial therapy pose a dilemma. Inadequate therapy, misdiagnosis, or a pneumonia-related complication (e.g., empyema or lung abscess) must all be considered. A diagnostic evaluation should be repeated, including resampling of the lower respiratory tract for quantitative cultures (using a lower diagnostic threshold when interpreting quantitative microbiology given recent antibiotic exposure) and consideration of broadened coverage until new data become available.

Current literature suggests a discrepancy between the standard of care discussed herein and contemporary clinical practice. Rello et al.<sup>156</sup> reported that, in a cohort of 113 patients with VAP, nearly 25 per cent received inadequate initial therapy. In a second cohort study of 398 ICU patients with suspected VAP from 20 ICUs throughout the U.S., Kollef et al.<sup>25</sup> documented more than 100 different antibiotic regimens prescribed as initial therapy of VAP. Furthermore, the mean duration of therapy was  $11.8 \pm 5.9$  days, and in 61.6 per cent of cases, there was not escalation de-escalation. The use of standardized treatment protocols can substantially improve the likelihood that adequate therapy is delivered for an appropriate duration. Ibrahim et al.<sup>135</sup> compared outcomes before and after implementation of a VAP treatment protocol that involved standardized, broad-spectrum initial coverage, with termination after 7 days absent persistent signs of active infection. The proportions of patients who received inadequate initial therapy and therapy of inappropriate duration were significantly lower in the protocol arm. Several additional studies have confirmed the effectiveness of protocol-driven therapy.<sup>157, 158</sup>

## Conclusions

VAP remains a common and problematic disease. Fortunately, health care practitioners may intervene successfully at several points in the natural history of VAP. Curtailing the incidence of VAP begins with

implementation of evidence-based preventive measures. When the diagnosis of VAP is suspected clinically, it must be confirmed microbiologically through the culture of lower respiratory tract samples, which is accomplished most effectively via quantitative cultures obtained using bronchoscopy. Broad-spectrum antimicrobial therapy must be initiated promptly, although preferably not before sputum specimen collection. Adequate initial therapy based on individual patient risk factors and institutional antibiograms is imperative to maximize survival. However, de-escalation and short-course therapy, when appropriate, are equally important in deterring the emergence of MDR pathogens. Finally, it is through continued research that evidence-based recommendations will emerge to elucidate current areas of controversy and inspire novel therapies in the management of VAP.

#### REFERENCES

- Garner JS, Jarvis WR, Emori TG, et al. CDC guidelines for nosocomial infections. *Am J Infect Control* 1988;16:128-40.
- Kollef MH, Shorr A, Tabak YP, et al. Epidemiology and outcomes of health-care-associated pneumonia. *Chest* 2005;128:3854-62.
- American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. *Am J Respir Crit Care Med* 2005;171:388-416.
- Vincent JL, Bihari DJ, Suter PM, et al. The prevalence of nosocomial infection in intensive care units in Europe: Results of the European Prevalence of Infection in Intensive Care (EPIC) study. *JAMA* 1995;274:639-44.
- Rello J, Ollendorf DA, Oster G, et al. Epidemiology and outcomes of ventilator-associated pneumonia in a large U.S. database. *Chest* 2002;122:2115-21.
- Chastre J, Fagon J-Y. Ventilator-associated pneumonia. *Am J Respir Crit Care Med* 2002;165:867-903.
- George DL. Epidemiology of nosocomial pneumonia in intensive care units patients. *Clin Chest Med* 1995;16:29-44.
- Meduri GU, Mauldin GL, Wunderink RG, et al. Causes of fever and pulmonary densities in patients with clinical manifestations of ventilator-associated pneumonia. *Chest* 1994;106:221-35.
- Fagon JY, Chastre J, Wolff M, et al. Invasive and noninvasive strategies for management of suspected ventilator-associated pneumonia. A randomized trial. *Ann Intern Med* 2000;132:621-30.
- Safdar N, Dezfulian C, Collard HR, Saint S. Clinical and economic consequences of ventilator-associated pneumonia: A systematic review. *Crit Care Med* 2005;33:2184-93.
- National Nosocomial Infections Surveillance (NNIS). Data summary from January 1992-April 2000, issued June 2000. *Am J Infect Control* 2000;28:429-48.
- Cook DJ, Walter SD, Cook RJ, et al. Incidence and risk factors for ventilator-associated pneumonia in critically ill patients. *Ann Intern Med* 1998;129:433-40.
- Celis R, Torres A, Gatell JM, et al. Nosocomial pneumonia: A multivariate analysis of risk and prognosis. *Chest* 1988;93:318-24.
- Torres A, Aznar R, Gatell JM, et al. Incidence, risk, and prognosis factors of nosocomial pneumonia in mechanically ventilated patients. *Am Rev Respir Dis* 1990;142:523-8.
- Brochard L, Mancebo J, Wysocki M, et al. Noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease. *N Engl J Med* 1995;333:817-22.
- Antonelli M, Conti G, Rocco M, et al. A comparison of noninvasive positive pressure ventilation and conventional mechanical ventilation in patients with acute respiratory failure. *N Engl J Med* 1998;339:429-35.
- Hilbert G, Gruson D, Vargas F, et al. Noninvasive ventilation in immunosuppressed patients with pulmonary infiltrates, fever, and acute respiratory failure. *N Engl J Med* 2001;344:817-22.
- Chastre J, Trouillet JL, Vuagnat A, et al. Nosocomial pneumonia in patients with acute respiratory distress syndrome. *Am J Respir Crit Care Med* 1998;157:1165-72.
- Delclaux C, Roupie E, Blot F, et al. Lower respiratory tract colonization and infection during severe acute respiratory distress syndrome: Incidence and diagnosis. *Am J Respir Crit Care Med* 1997;156:1092-8.
- Markowicz P, Wolff M, Djedaini K, et al. Multicenter prospective study of ventilator-associated pneumonia during acute respiratory distress syndrome. Incidence, prognosis, and risk factors. ARDS Study Group. *Am J Respir Crit Care Med* 2000;161:1942-8.
- Barie PS. Importance, morbidity, and mortality of pneumonia in the surgical intensive care unit. *Am J Surg* 2000;197:S2-7.
- Haley RW, Hooton TM, Culver DH, et al. Nosocomial infections in U.S. hospitals, 1975-1976: Estimated frequency by selected characteristics of patients. *Am J Med* 1981;70:947-59.
- Pennington JE. Nosocomial respiratory infection. In: Mandell GL, Douglas RG Jr, Bennet JE, eds. *Principles and Practice of Infectious Diseases*. St. Louis, MO: Churchill Livingstone, 1990, pp 2199-205.
- Centers for Disease Control and Prevention. Monitoring hospital acquired infections to promote patient safety: United States, 1990-1999. *Morbid Mortal Wkly Rep* 2000;49:149-53.
- Kollef MH, Morrow LE, Niederman MS, et al. Clinical characteristics and treatment patterns among patients with ventilator-associated pneumonia. *Chest* 2006;129:1210-8.
- Craven DE, Kunches LM, Kilinsky V, et al. Risk factors for pneumonia and fatality in patients receiving continuous mechanical ventilation. *Am Rev Respir Dis* 1986;133:792-6.
- Heyland DK, Cook DJ, Griffith L, et al. The attributable morbidity and mortality of ventilator-associated pneumonia in the critically ill patient. *Am J Respir Crit Care Med* 1999;159:1249-56.
- Kollef MH, Ward S, Sherman G, et al. Inadequate treatment of nosocomial infections is associated with certain empiric antibiotic choices. *Crit Care Med* 2000;28:3456-64.
- Hugonnet S, Eggiman P, Borst F, et al. Impact of ventilator-associated pneumonia on resource utilization and patient outcome. *Infect Control Hosp Epidemiol* 2004;25:1090-6.
- Johanson WG, Pierce AK, Sanford JP. Changing pharyngeal bacterial flora of hospitalized patients: Emergence of gram negative bacilli. *N Engl J Med* 1969;281:1137-40.
- Johanson WG, Pierce AK, Sanford JP, et al. Nosocomial respiratory infections with gram-negative bacilli: The significance of colonization of the respiratory tract. *Ann Intern Med* 1972;77:701-6.

32. Bonten MJ, Bergmans DC, Ambergen AW, et al. Risk factors for pneumonia, and colonization of respiratory tract and stomach in mechanically ventilated ICU patients. *Am J Respir Crit Care Med* 1996;154:1339-46.
33. Trouillet JL, Chastre J, Vuagnat A, et al. Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. *Am J Respir Crit Care Med* 1998;157:531-9.
34. Neuhauser MM, Weinstein RA, Rydman R, et al. Antibiotic resistance among gram-negative bacilli in U.S. intensive care units: Implications for fluoroquinolone use. *JAMA* 2003;289:885-8.
35. Garnacho-Montero J, Ortiz-Leyba C, Jimenez-Jimenez FJ, et al. Treatment of multidrug-resistant *Acinetobacter baumannii* ventilator-associated pneumonia (VAP) with intravenous colistin: A comparison with imipenem-susceptible VAP. *Clin Infect Dis* 2003;36:1111-8.
36. Richards MJ, Edwards JR, Culver DH, et al. Nosocomial infections in medical intensive care units in the United States: National Nosocomial Infections Surveillance System. *Crit Care Med* 1999;27:887-92.
37. Lowy FD. *Staphylococcus* infections. *N Engl J Med* 1998;320:520-32.
38. Fridkin SK. Increasing prevalence of antimicrobial resistance in intensive care units. *Crit Care Med* 2001;29:N64-8.
39. Scheld WM. Maintaining fluoroquinolone class efficacy: Review of influencing factors. *Emerg Infect Dis* 2003;9:1-9.
40. National Nosocomial Infections Surveillance (NNIS) System Report. Data summary from January 1992 through June 2003, issued August 2003. *Am J Infect Control* 2003;31:481-98.
41. Marik PE, Careau P. The role of anaerobes in patients with ventilator-associated pneumonia and aspiration pneumonia: A prospective study. *Chest* 1999;115:178-83.
42. El-Ebiary M, Torres A, Fabregas N, et al. Significance of the isolation of *Candida* species from respiratory samples in critically ill, non-neutropenic patients. *Am J Respir Crit Care Med* 1997;156:583-90.
43. Krasinski K, Holzman RS, Hanna B, et al. Nosocomial fungal infection during hospital renovation. *Infect Control* 1985;6:278-82.
44. Lentino JR, Rosenkranz MA, Michaels JA, et al. A retrospective review of airborne disease secondary to road construction and contaminated air conditioners. *Am J Epidemiol* 1982;116:430-7.
45. Loo VG, Bertrand C, Dixon C, et al. Control of construction-associated nosocomial aspergillosis in an antiquated hematology unit. *Infect Control Hosp Epidemiol* 1996;17:360-4.
46. Girou E, Loyeau S, Legrand P, et al. Efficacy of hand rubbing with alcohol based solution versus standard hand washing with antiseptic soap: Randomized clinical trial. *Br Med J* 2002;325:362-6.
47. Pittet D, Hugonnet S, Harbarth S, et al. Effectiveness of a hospital-wide programme to improve compliance with hand hygiene. *Lancet* 2000;356:1307-12.
48. Girou E, Brun-Buisson C, Taille S, et al. Secular trends in nosocomial infections and mortality associated with noninvasive ventilation in patients with exacerbations of COPD and pulmonary edema. *JAMA* 2003;290:2985-91.
49. Kress J, Pohlman A, O'Connor M, Hall J. Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation. *N Engl J Med* 2000;342:1471-7.
50. Marelich GP, Murin S, Battistella F, et al. Protocol weaning of mechanical ventilation in medical and surgical patients by respiratory care practitioners and nurses: Effect on weaning time and incidence of ventilator-associated pneumonia. *Chest* 2000;118:459-67.
51. Holzapfel L, Chevret S, Madinier G, et al. Influence of long-term oro- or nasotracheal intubation on nosocomial maxillary sinusitis and pneumonia: Results of a prospective, randomized trial. *Crit Care Med* 1993;21:1132-8.
52. Rouby JJ, Laurent P, Gosnach M, et al. Risk factors and clinical relevance of nosocomial maxillary sinusitis in the critically ill. *Am J Respir Crit Care Med* 1994;150:776-83.
53. Cook D, De Jonghe B, Brochard L, Brun-Buisson C. Influence of airway management on ventilator-associated pneumonia: Evidence from randomized trials. *JAMA* 1998;279:781-7.
54. Valles J, Artigas A, Rello J, et al. Continuous aspiration of subglottic secretions in preventing ventilator-associated pneumonia. *Ann Intern Med* 1995;122:179-86.
55. Cook D, De Jonghe B, Brochard-Ferrer M, et al. Utility of selective digestive decontamination in mechanically ventilated patients. *Ann Intern Med* 1994;120:389-95.
56. Mahul P, Auboyer C, Jospe R, et al. Prevention of nosocomial pneumonia in intubated patients: Respective role of mechanical subglottic secretions drainage and stress ulcer prophylaxis. *Intensive Care Med* 1992;18:20-5.
57. Pneumatikos I, Koulouras V, Nathanail C, et al. Selective decontamination of subglottic area in mechanically ventilated patients with multiple trauma. *Intensive Care Med* 2002;28:432-7.
58. Kollef MH, Skubas NJ, Sundt TM. A randomized clinical trial of continuous aspiration of subglottic secretions in cardiac surgery patients. *Chest* 1999;116:1339-46.
59. Smulders K, van der Hoeven H, Weers-Pothoff I, et al. A randomized clinical trial of intermittent subglottic secretion drainage in patients receiving mechanical ventilation. *Chest* 2002;121:858-62.
60. Torres A, Serra-Batlles J, Ros E, et al. Pulmonary aspiration of gastric contents in patients receiving mechanical ventilation: The effect of body position. *Ann Intern Med* 1992;116:540-3.
61. Orozco-Levi M, Torres A, Ferrer M, et al. Semirecumbent position protects from pulmonary aspiration but not completely from gastroesophageal reflux in mechanically ventilated patients. *Am J Respir Crit Care Med* 1995;152:1387-90.
62. Drakulovic MB, Torres A, Bauer TT, et al. Supine body position as a risk factor for nosocomial pneumonia in mechanically ventilated patients: A randomized trial. *Lancet* 1999;354:1851-8.
63. Heyland DK, Drover J, MacDonald S, et al. Effect of postpyloric feeding on gastroesophageal regurgitation and pulmonary microaspiration: Results of a randomized controlled trial. *Crit Care Med* 2001;29:1495-501.
64. Kearns PJ, Chin D, Mueller L, et al. The incidence of ventilator-associated pneumonia and success in nutrient delivery with gastric versus small intestinal feeding: A randomized clinical trial. *Crit Care Med* 2000;28:1742-6.
65. Montejo JC, Grau T, Acosta J, et al. Multicenter, prospective, randomized, single-blind study comparing the efficacy and gastrointestinal complications of early jejunal feeding with early gastric feeding in critically ill patients. *Crit Care Med* 2002;30:796-800.
66. Heyland DK, Dhaliwal R, Drover JW, et al. Canadian clinical practice guidelines for nutrition support in mechanically ven-

tilated, critically ill adult patients. *J Parenter Enter Nutr* 2003;27:355-73.

67. Tablan OC, Anderson LJ, Besser R, et al., Healthcare Infection Control Practices Advisory Committee, Centers for Disease Control and Prevention. Guidelines for preventing healthcare-associated pneumonia, 2003: Recommendations of the CDC and the Healthcare Infection Control Practices Advisory Committee. *Morbidity Mortality Weekly Report* 2004;53(RR-3):1-36.

68. Berne JD, Norwood SH, McAuley CE, et al. Erythromycin reduces delayed gastric emptying in critically ill trauma patients: A randomized, controlled trial. *J Trauma* 2002;53:422-5.

69. Ibrahim EH, Mehringer L, Prentice D, et al. Early versus late enteral feeding of mechanically ventilated patients: results of a clinical trial. *J Parenter Enter Nutr* 2002;26:174-81.

70. Shorr AF, Duh MS, Kelly KM, Kollef MH. Red blood cell transfusion and ventilator-associated pneumonia: A potential link? *Crit Care Med* 2004;32:666-74.

71. Abele-Horn M, Dauber A, Bauernfeind A, et al. Decrease in nosocomial pneumonia in ventilated patients by selective oropharyngeal decontamination (SOD). *Intensive Care Med* 1997;23:187-95.

72. Pugin J, Auckenthaler R, Lew DP, Suter PM. Oropharyngeal decontamination decreases incidence of ventilator-associated pneumonia: A randomized, placebo-controlled, double-blind clinical trial. *JAMA* 1991;265:2704-10.

73. Rodriguez-Roldan JM, Altuna-Cuesta A, Lopez A, et al. Prevention of nosocomial lung infection in ventilated patients: Use of an antimicrobial pharyngeal nonabsorbable paste. *Crit Care Med* 1990;18:1239-42.

74. Krueger WA, Lenhart FP, Neeser G, et al. Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: A prospective, stratified, randomized, double-blind, placebo-controlled clinical trial. *Am J Respir Crit Care Med* 2002;166:1029-37.

75. de Jonge E, Schultz M, Spanjaard L, et al. Effects of selective decontamination of the digestive tract on mortality and acquisition of resistant bacteria in intensive care: A randomized controlled trial. *Lancet* 2003;362:1011-6.

76. de la Cal MA, Cerda E, Garcia-Hierro P, et al. Survival benefit in critically ill burned patients receiving selective decontamination of the digestive tract: A randomized, placebo-controlled, double-blind trial. *Ann Surg* 2005;241:424-30.

77. van Nieuwenhoven CA, Buskens E, van Tiel FH, Bonten MJ. Relationship between methodological trial quality and the effects of selective digestive decontamination on pneumonia and mortality in critically ill patients. *JAMA* 2001;286:335-40.

78. Verwaest C, Verhaegen J, Ferdinande P, et al. Randomized, controlled trial of selective digestive decontamination in 600 mechanically ventilated patients in a multidisciplinary intensive care unit. *Crit Care Med* 1997;25:63-71.

79. Misset B, Kitzis MD, Conscience G, et al. Mechanisms of failure to decontaminate the gut with polymyxin E, gentamycin and amphotericin B in patients in intensive care. *Eur J Clin Microbiol Infect Dis* 1994;13:165-70.

80. Lingnau W, Berger J, Javorsky F, et al. Changing bacterial ecology during a five year period of selective intestinal decontamination. *J Hosp Infect* 1998;39:195-206.

81. DeRiso AJ, Ladowski JS, Dillon TA, et al. Chlorhexidine gluconate 0.12% oral rinse reduces the incidence of total nosoco-

mial respiratory infection and nonprophylactic systemic antibiotic use in patients undergoing heart surgery. *Chest* 1996;109:1556-61.

82. Fourrier F, Dubois D, Pronnier P, et al. Effect of gingival and dental plaque antiseptic decontamination on nosocomial infections acquired in the intensive care unit: A double-blind placebo-controlled multicenter study. *Crit Care Med* 2005;33:1728-35.

82A. Chlebicki MP, Safdar N. Topical chlorhexidine for prevention of ventilator-associated pneumonia: A meta-analysis. *Crit Care Med* 2007;35:595-602.

83. Bonten MJ, Gaillard CA, de Leeuw PW, Stobberingh EE. Role of colonization of the upper intestinal tract in the pathogenesis of ventilator-associated pneumonia. *Clin Infect Dis* 1997;24:309-19.

84. Prod'homme G, Leuenberger P, Koerfer J, et al. Nosocomial pneumonia in mechanically ventilated patients receiving antacid, ranitidine or sucralfate as prophylaxis for stress ulcer: A randomized controlled trial. *Ann Intern Med* 1994;120:653-62.

85. Cook D, Guyatt G, Marshall J, et al. A comparison of sucralfate and ranitidine for the prevention of upper gastrointestinal bleeding in patients requiring mechanical ventilation. *N Engl J Med* 1998;338:791-7.

86. Driks MR, Craven DE, Celli BR, et al. Nosocomial pneumonia in intubated patients given sucralfate as compared with antacids or histamine type 2 blockers: The role of gastric colonization. *N Engl J Med* 1987;317:1376-82.

87. Tryba M. Risks of acute stress bleeding and nosocomial pneumonia in ventilated intensive care unit patients: Sucralfate versus antacids. *Am J Med* 1987;83:117-24.

88. Bonten MJ, Gaillard CA, van der Geest S, et al. The role of intragastric acidity and stress ulcer prophylaxis on colonization and infection in mechanically ventilated ICU patients: A stratified, randomized, double-blind study of sucralfate versus antacids. *Am J Respir Crit Care Med* 1995;152:1825-34.

89. Bonten MJM, Gaillard CA, van Tiel FH, et al. The stomach is not a source for colonization of the upper respiratory tract and pneumonia in ICU patients. *Chest* 1994;105:878-84.

90. Braga M, Vignali A, Radaelli G, et al. Association between perioperative blood transfusion and postoperative infection in patients having elective operations for gastrointestinal cancer. *Eur J Surg* 1992;158:531-6.

91. Ottino G, De Paulis R, Pansini S, et al. Major sternal wound infection after open heart surgery: A multivariate analysis of risk factors in 2,579 consecutive procedures. *Ann Thorac Surg* 1987;44:173-9.

92. Dellinger EP, Miller SD, Wertz MJ, et al. Risk of infection after open fracture of the arm or leg. *Arch Surg* 1988;123:1320-7.

93. Claridge JA, Sawyer RG, Schulman AM, et al. Blood transfusions correlate with infections in trauma patients in a dose-dependent manner. *Am Surg* 2002;68:566-72.

94. Taylor RW, Manganaro L, O'Brien J, et al. Impact of allogenic packed red blood cell transfusion on nosocomial infection rates in the critically ill patient. *Crit Care Med* 2002;30:2249-54.

95. Earley AS, Gracias VH, Haut E, et al. Anemia management program reduces transfusion volumes, incidence of ventilator-associated pneumonia, and cost in trauma patients. *J Trauma* 2006;61:1-7.

96. Carlet J, Ben Ali A, Chalfine A. Epidemiology and control of antibiotic resistance in the intensive care unit. *Curr Opin Infect Dis* 2004;17:309-16.

97. Fridkin SK, Gaynes RP. Antimicrobial resistance in intensive care units. *Clin Chest Med* 1999;20:303-16.
98. Kollef MH, Vlasnik J, Sharpless L, et al. Scheduled rotation of antibiotic classes: A strategy to decrease the incidence of ventilator-associated pneumonia due to antibiotic-resistant gram-negative bacteria. *Am J Respir Crit Care Med* 1997;156:1040-8.
99. Gruson D, Hilbert G, Vargas F, et al. Strategy of antibiotic rotation: Long term effect on incidence and susceptibilities of gram-negative bacilli responsible for ventilator-associated pneumonia. *Crit Care Med* 2003;31:1908-14.
100. Raymond DP, Pelletier SJ, Crabtree TD, et al. Impact of a rotating empiric antibiotic schedule on infectious mortality in an intensive care unit. *Crit Care Med* 2001;29:1101-8.
101. van Loon HJ, Vriens MR, Fluit AC, et al. Antibiotic rotation and development of gram-negative antibiotic resistance. *Am J Respir Crit Care Med* 2005;171:480-7.
102. Kollef MH. Is antibiotic cycling the answer to preventing the emergence of bacterial resistance in the intensive care unit? *Clin Infect Dis* 2006;43:S82-8.
103. Zazk JE, Garrison T, Trovillion E, et al. Effect of an education program aimed at reducing the occurrence of ventilator-associated pneumonia. *Crit Care Med* 2002;30:2407-12.
104. Niederman MS. Appropriate use of antimicrobial agents: Challenges and strategies for improvement. *Crit Care Med* 2003;31:608-16.
105. Alvarez-Lerma F. Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit: ICU-Acquired Pneumonia Study Group. *Intensive Care Med* 1996;22:387-94.
106. Fabregas N, Ewig S, Torres A, et al. Clinical diagnosis of ventilatory associated pneumonia revisited: Comparative value using immediate post mortem lung biopsies. *Thorax* 1999;54:867-73.
107. Fagon JY, Chastre J, Hance AJ, et al. Evaluation of clinical judgment in the identification and treatment of nosocomial pneumonia in ventilated patients. *Chest* 1993;103:547-55.
108. Baughman RP. Diagnosis of ventilator-associated pneumonia. *Curr Opin Crit Care* 2003;95:397-402.
109. Mabie M, Wunderink RG. Use and limitations of clinical and radiologic diagnosis of pneumonia. *Semin Respir Infect* 2003;18:72-9.
110. Fagon JY, Chastre J, Domart Y, et al. Nosocomial pneumonia in patients receiving continuous mechanical ventilation. Prospective analysis of 52 episodes with use of a protected specimen brush and quantitative culture techniques. *Am Rev Respir Dis* 1989;139:877-84.
111. Rodriguez de Castro F, Sole-Violan J, Aranda Leon A, et al. Do quantitative cultures of protected brush specimens modify the initial empirical therapy in ventilated patients with suspected pneumonia? *Eur Respir J* 1996;9:37-41.
112. Pugin J, Auckenthaler R, Mili N, et al. Diagnosis of ventilator-associated pneumonia by bacteriologic analysis of bronchoscopic and nonbronchoscopic "blind" bronchoalveolar lavage fluid. *Am Rev Respir Dis* 1991;143:1121-9.
113. Singh N, Rogers P, Atwood CW, et al. Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. *Am J Respir Crit Care Med* 2000;162:505-11.
114. Fartoukh M, Maitre B, Honore S, et al. Diagnosing pneumonia during mechanical ventilation: The clinical pulmonary infection score revisited. *Am J Respir Crit Care Med* 2003;168:173-9.
115. Luyt CE, Chastre J, Fagon J, et al. Value of the clinical pulmonary infection score for the identification and management of ventilator-associated pneumonia. *Intensive Care Med* 2004;30:844-52.
116. Veinstein A, Brun-Buisson C, Derrode N, et al. Validation of an algorithm based on direct examination of specimens in suspected ventilator-associated pneumonia. *Intensive Care Med* 2006;32:676-83.
117. Centers for Disease Control and Prevention. National Nosocomial Infections Surveillance System (NNIS). Available at <http://www.cdc.gov/ncidod/dhqp/nnis.html>; accessed March 10, 2007.
118. Miller PR, Johnson JC III, Karchmer T, et al. National nosocomial infection surveillance system: From benchmark to bedside in trauma patients. *J Trauma* 2006;60:98-103.
119. Blot FB, Raynard B, Chachaty E, et al. Value of gram stain examination of lower respiratory tract secretions for early diagnosis of nosocomial pneumonia. *Am J Respir Crit Care Med* 2000;162:1731-7.
120. Torres A, Mustafa E. Bronchoscopic BAL in the diagnosis of ventilator-associated pneumonia. *Chest* 2000;117:198-202.
121. Niederman MS. Gram-negative colonization of the respiratory tract: Pathogenesis and clinical consequences. *Semin Respir Infect* 1990;5:173-84.
122. Vidaur L, Gualis B, Rodriquez A, et al. Clinical resolution in patients with suspicion of VAP: A cohort study comparing patients with and without ARDS. *Crit Care Med* 2005;33:1248-53.
123. Souweine B, Veber B, Bedos JP, et al. Diagnostic accuracy of protected specimen brush and bronchoalveolar lavage in nosocomial pneumonia: Impact of previous antimicrobial treatment. *Crit Care Med* 1998;26:236-44.
124. Elatrous S, Boukef R, Besbes LO, et al. Diagnosis of ventilator-associated pneumonia: Agreement between quantitative cultures of endotracheal aspiration and plugged telescoping catheter. *Intensive Care Med* 2004;30:853-8.
125. Wu CL, Yang DI, Wang NY, et al. Quantitative culture of endotracheal aspirates in the diagnosis of ventilator associated pneumonia in patients with treatment failure. *Chest* 2002;122:662-8.
126. Brun-Buisson C, Fartoukh M, Lechapt E, et al. Contribution of blinded, protected quantitative specimens to the diagnostic and therapeutic management of ventilator-associated pneumonia. *Chest* 2005;128:533-44.
127. Sanchez-Nieto JM, Torres A, Garcia-Cordoba F, et al. Impact of invasive and noninvasive quantitative culture sampling on outcome of ventilator-associated pneumonia. *Am J Respir Crit Care Med* 1998;157:371-6.
128. Campbell GD. Blinded invasive diagnostic procedures in ventilator-associated pneumonia. *Chest* 2000;117:207S-11S.
129. Ruiz M, Torres A, Ewig S, et al. Noninvasive versus invasive microbial investigation in ventilator-associated pneumonia: Evaluation of outcome. *Am J Respir Crit Care Med* 2000;162:119-25.
130. Shorr AF, Sherner JH, Jackson WL, Kollef MH. Invasive approaches to the diagnosis of ventilator-associated pneumonia: A meta-analysis. *Crit Care Med* 2005;33:46-53.
- 130A. The Canadian Critical Care Trials Group. A randomized

trial of diagnostic techniques for ventilator-associated pneumonia. *N Engl J Med* 2006;355:2619–30.

131. Bonten MJ, Bergmans DC, Stobberingh EE, et al. Implementation of bronchoscopic techniques in the diagnosis of ventilator-associated pneumonia to reduce antibiotic use. *Am J Respir Crit Care Med* 1997;156:1820–4.

132. Croce MA, Fabian TC, Schurr MJ, et al. Using bronchoalveolar lavage to distinguish nosocomial pneumonia from systemic inflammatory response syndrome: A prospective analysis. *J Trauma* 1995;39:1134–9.

133. Kollef MH, Kollef KE. Antibiotic utilization and outcomes for patients with clinically suspected VAP and negative quantitative BAL cultures results. *Chest* 2005;128:2706–13.

134. Iregui M, Ward S, Sherman G, et al. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. *Chest* 2002;122:262–8.

135. Ibrahim EH, Ward S, Sherman G, et al. Experience with a clinical guideline for the treatment of ventilator associated pneumonia. *Crit Care Med* 2001;29:1109–15.

136. Gruson D, Hilbert G, Vargas F, et al. Rotation and restricted use of antibiotics in a medical intensive care unit: Impact on the incidence of ventilator-associated pneumonia caused by antibiotic resistant gram-negative bacteria. *Am J Respir Crit Care Med* 2000;162:837–43.

137. Rello J, Sa-Borges M, Correa H, et al. Variations in etiology of ventilator-associated pneumonia across four treatment Sites. Implications for antimicrobial prescribing practices. *Am J Respir Crit Care Med* 1999;160:608–13.

138. Paladino JA. Pharmacoeconomic comparison of sequential IV/oral ciprofloxacin versus ceftazidime in the treatment of nosocomial pneumonia. *Can J Hosp Pharm* 1995;48:276–83.

139. Brown RB, Kruse JA, Counts GW, et al., Endotracheal Tobramycin Study Group. Double-blind study of endotracheal tobramycin in the treatment of gram-negative bacterial pneumonia. *Antimicrob Agents Chemother* 1990;34:269–72.

140. Guillemot D, Carbon C, Balkau B, et al. Low dosage and long treatment duration of  $\beta$ -lactam: Risk factors for carriage of penicillin-resistant *Streptococcus pneumoniae*. *JAMA* 1998;279:365–70.

141. Conte JE Jr, Golden JA, Kipps J, Zurlinden E. Intrapulmonary pharmacokinetics of linezolid. *Antimicrob Agents Chemother* 2002;46:1475–80.

142. Rubinstein E, Cammarata S, Oliphant T, Wunderink R, Linezolid Nosocomial Pneumonia Study Group. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double blind, multicenter study. *Clin Infect Dis* 2001;32:402–12.

143. Wunderink RG, Cammarata SK, Oliphant TH, Kollef MH. Linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia: Continuation of a randomized, double-blind, multicenter study. *Clin Ther* 2003;25:980–92.

144. Kollef MH, Rello J, Cammarata S, et al. Clinical cure and survival in Gram-positive ventilator-associated pneumonia: Retrospective analysis of two double-blind studies comparing linezolid with vancomycin. *Intensive Care Med* 2004;30:388–94.

145. Machado AR, Arns C, Follador W, Guerra A. Cost-effectiveness of linezolid versus vancomycin in mechanical ventilation-associated nosocomial pneumonia caused by methicillin-resistant *Staphylococcus aureus*. *Braz J Infect Dis* 2005;9:191–200.

146. Grau S, Alvarez-Lerma F, del Castillo A, et al. Cost-effectiveness analysis of the treatment of ventilator-associated pneumonia with linezolid or vancomycin in Spain. *J Chemother* 2005;17:203–11.

147. Nsier S, Pompeo C, Soubrier S, et al. First-generation fluoroquinolone use and subsequent emergence of multiple drug-resistant bacteria in the intensive care unit. *Crit Care Med* 2005;33:283–9.

148. Trouillet J, Vuagnat A, Combes A, et al. *Pseudomonas aeruginosa* ventilator-associated pneumonia: Comparison of episodes due to piperacillin-resistant versus piperacillin-susceptible organisms. *Clin Infect Dis* 2002;34:1047–54.

149. Daniel F, Sahn D, Critchley I, et al. Evaluation of current activities of fluoroquinolones against gram-negative bacilli using centralized in vitro testing and electronic surveillance. *Antimicrob Agents Chemother* 2001;45:267–74.

150. Hilf M, Yu VL, Sharp J, et al. Antibiotic therapy for *Pseudomonas aeruginosa* bacteremia: Outcome correlations in a prospective study of 200 patients. *Am J Med* 1989;87:540–6.

151. Fowler RA, Flavin KE, Barr J, et al. Variability in antibiotic prescribing patterns and outcomes in patients with clinically suspected ventilator-associated pneumonia. *Chest* 2003;123:835–44.

152. Paul M, Benuri-Silibiger I, Soares-Weiser K, Leibovici L.  $\beta$ -Lactam monotherapy versus  $\beta$ -lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: Systematic review and meta-analysis of randomized trials. *Br Med J* 2004;328:668–81.

153. Luna CM, Blanzaco D, Niederman MS, et al. Resolution of ventilator-associated pneumonia: Prospective evaluation of the clinical pulmonary infection score as an early clinical predictor of outcome. *Crit Care Med* 2003;31:676–82.

154. Dennesen PJW, van der Ven JA, Alphons GH, et al. Resolution of infectious parameters after antimicrobial therapy in patients with ventilator-associated pneumonia. *Am J Respir Crit Care Med* 2001;163:1371–5.

155. Chastre J, Wolff M, Fagon JY, et al. Comparison of 8 vs. 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: A randomized trial. *JAMA* 2002;290:2588–98.

156. Rello J, Gallego M, Mariscal D, et al. The value of routine microbial investigation in ventilator-associated pneumonia. *Am J Respir Crit Care Med* 1997;156:196–200.

157. Evans RS, Pestotnik SL, Classen DC, et al. A computer-assisted management program for antibiotics and other anti-infective agents. *N Engl J Med* 1998;338:232–8.

158. Micek ST, Ward S, Fraser V, Kollef M. A randomized controlled trial of an antibiotic discontinuation policy for clinically suspected ventilator-associated pneumonia. *Chest* 2004;125:1791–9.